Ndemann RK, Bolden JE, Newbold A, Cluse LA et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not demand death receptor signaling or maybe a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 2009; 114: 380?93. 38. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L et al. Analysis on the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007; 104: 8071?076. 39. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833?0838. 40. Wu D, Smyth GK. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res 2012; 40: e133. 41. Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I et al. Bortezomib alone or in combination using the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone illness within the 5T2MM murine model of myeloma. Cancer Res 2009; 69: 5307?311. 42. Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative tension and DNA harm. Br J Haematol 2007; 139: 385?97. 43. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055?062. 44. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2004; 12: 228?37. 45. Guo F, Sigua C, Tao J, Bali P, George P, Li Y et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.Price of Vanadium(IV)bis(acetylacetonato)oxide Cancer Res 2004; 64: 2580?589.[(3-Bromocyclobutoxy)methyl]benzene Order 46.PMID:23937941 Kauh J, Fan S, Xia M, Yue P, Yang L, Khuri FR et al. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One particular 2010; 5: e10376. 47. Perez LE, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C et al. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in aspect by regulating c-FLIP. J Immunol 2008; 180: 1545?555. 48. Gomez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, ascertain sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 2007; 313: 2378?388. 49. Brennan SK, Matsui W. Cancer stem cells: controversies in numerous myeloma. J Mol Med (Berl) 2009; 87: 1079?085. 50. Labrinidis A, Diamond P, Martin S, Hay S, Liapis V, Zinonos I et al. Apo2L/TRAIL inhibits tumor growth and bone destruction within a murine model of various myeloma. Clin Cancer Res 2009; 15: 1998?009. 51. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces roughly 1000-fold resistance to ABT737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403?413. 52. Vogler M, Dinsdale D, Dyer MJS, Cohen GM. Bcl-2 inhibitors: smaller molecules having a large influence on cancer therapy. Cell Death Differ 2008; 16: 360?67. 53. Bradford M.
